Mr. Hugh Rogers reports

BIONXT REPORTS "READINESS TO GRANT" PATENT NOTIFICATION FROM THE EURASIAN PATENT ORGANIZATION

The Eurasian Patent Organization (EAPO) has issued a readiness-to-grant notification for the company's comprehensive patent application for sublingual delivery of anti-cancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including Bionxt's lead product, BNT23001, a sublingual thin-film formulation of cladribine for the treatment of multiple sclerosis (MS).

The EAPO is expected to grant the formal patent to Bionxt upon payment of a publication fee, which the company will provide to the EAPO this week. The EAPO covers Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan and Turkmenistan. These countries are the members of the Eurasian Patent Convention (EAPC), which provides a single, harmonized patent application process and regulator for the region. The EAPO grants Eurasian patents that are valid in all eight member states with a combined population of over 200 million.

"Solidifying patent protection is a critical part of our commercialization strategy," said Hugh Rogers, chief executive officer of Bionxt. "The timing is excellent as the company is days away from commencing a two-week-long large-mass animal bioequivalence study to determine dosing parameters for our upcoming human bioequivalence study. The coming months are expected to be very exciting for Bionxt as multiple clinical programs advance and our intellectual property portfolio gains international recognition and protection."

The patent nationalization process is under way in key global markets, including the European Union, Canada, Australia, Eurasia, New Zealand and Japan, as well as a Track 1 priority filing in the United States. Both the European Patent Office and the Eurasian Patent Office have issued favourable communications, including the formal acceptance of novelty, inventive step and industrial applicability.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and the OTC Markets under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.